登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>Activin A >ACA-H421b

Human Activin A / INHBA Protein, Tag Free

分子别名(Synonym)

Activin A,INHBA

表达区间及表达系统(Source)

Human Activin A Protein, Tag Free (ACA-H421b) is expressed from human 293 cells (HEK293). It contains AA Gly 311 - Ser 426 (Accession # AAH07858.1).

Predicted N-terminus: Gly 311

Request for sequence

蛋白结构(Molecular Characterization)

Activin A Structure

This protein carries no "tag".

The protein has a calculated MW of 13.0 kDa. The protein migrates as 14-15 kDa under reducing (R) condition, and 23-25 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 0.1 EU per μg by the LAL method.

无菌(Sterility)

Negative

支原体(Mycoplasma)

Negative.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in 0.056% TFA in 30% ACN with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

Activin A SDS-PAGE

Human Activin A Protein, Tag Free on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

 

活性(Bioactivity)-ELISA

Activin A ELISA

Immobilized Human Activin A Protein, Tag Free (Cat. No. ACA-H421b) at 5 μg/mL (100 μL/well) can bind Human ACVR2A, Fc Tag (Cat. No. ACA-H5269) with a linear range of 0.4-25 ng/mL (QC tested).

Protocol

Activin A ELISA

Immobilized Human Activin A Protein, Tag Free (Cat. No. ACA-H421b) at 5 μg/mL (100 μL/well) can bind Biotinylated Human Activin RIIB Protein, His,Avitag (Cat. No. ACB-H82E3) with a linear range of 0.3-5 ng/mL (Routinely tested).

Protocol

 

活性(Bioactivity)-SPR

Activin A SPR

Human Activin RIIB, His Tag (Cat. No. ACB-H5226) immobilized on CM5 Chip can bind Human Activin A Protein, Tag Free (Cat. No. ACA-H421b) with an affinity constant of 0.216 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol

 

活性(Bioactivity)-Bioactivity CELL BASE

Activin A CELL

Human Activin A Protein, Tag Free (Cat. No. ACA-H421b) inhibits the proliferation of MPC-11 cells. The specific activity of Human Activin A Protein, Tag Free is > 5.00×10^2 IU/mg, which is calibrated against WHO Reference Reagent Activin A (Human, Recombinant) NIBSC code: 91/626 (Routinely tested).

Protocol

 
 
ACRO质量管理体系
 
 

背景(Background)

Activin and inhibin are two closely related protein complexes that have almost directly opposite biological effects. Activin enhances FSH biosynthesis and secretion, and participates in the regulation of the menstrual cycle. Many other functions have been found to be exerted by activin, including roles in cell proliferation, differentiation, apoptosis, metabolism, homeostasis, immune response, wound repair, and endocrine function. Conversely inhibin down regulates FSH synthesis and inhibits FSH secretion.Activins are nonglycosylated homodimers or heterodimers of various β subunits (βA, βB, βC, and βE in mammals), while Inhibins are heterodimers of a unique α subunit and one of the β subunits. Activin A is a widely expressed homodimer of two βA chains. The βA subunit can also heterodimerize with a βB or βC subunit to form Activin AB and Activin AC, respectively. The 14 kDa mature human βA chain shares 100% amino acid sequence identity with bovine, feline, mouse, porcine, and rat βA.

文献引用(Citations)

 

前沿进展

Engineered Hollow Nanocomplex Combining Photothermal and Antioxidant Strategies for Targeted Tregs Depletion and Potent Immune Activation in Tumor Immunotherapy
Sun, Wang, Ren et al
Adv Healthc Mater (2025)
Abstract: In the tumor immunosuppressive microenvironment (TIME), regulatory T cells (Tregs) critically suppress anticancer immunity, characterized by high expression of glucocorticoid-induced TNF receptor (GITR) expression and sensitivity to reactive oxygen species (ROS). This study develops a near-infrared (NIR)-responsive hollow nanocomplex (HPDA-OPC/DTA-1) using hollow polydopamine nanoparticles (HPDA), endowed with thermogenic and antioxidative properties, specifically targeting Tregs to activate antitumor immunity. The GITR agonist DTA-1, combined with the antioxidant oligomeric proanthocyanidins (OPC) to deplete Tregs. However, Tregs depletion alone may not sufficiently trigger robust immune responses. The HPDA nanocarrier enhances thermogenic and antioxidative capacities, supporting photothermal immunotherapy. The HPDA-OPC/DTA-1 demonstrates NIR responsiveness for both photothermal therapy (PTT) and OPC release, while facilitating Tregs depletion via DTA-1 and reducing ROS levels, thereby reviving antitumor immunity. Notably, intratumoral CD4+CD25+FOXP3+ Tregs exhibited a 4.08-fold reduction alongside a 49.11-fold increase in CD8+ T cells/Tregs relative to controls. Enhanced dendritic cells (DCs) maturation and immunogenic cell death (ICD) induction further demonstrate that HPDA-OPC/DTA-1 alleviates immunosuppression and activates antitumor immunity. Ultimately, the observed tumor inhibitory effect (tumor volume: 6.75-fold versus the control) and an over 80% survival rate highlight the therapeutic potential of combining Tregs targeting, antioxidant strategy, and photothermal immunotherapy for effective cancer treatment.© 2025 Wiley‐VCH GmbH.
Policymaker and stakeholder perspectives on determinants of fertility decisions through changing environmental and economic conditions in Greenland
Peterson, Rosing, Reimer et al
Health Place (2025) 92, 103443
Abstract: This study explored linkages between natural resources and determinants of fertility decisions in Greenland. Interviews were conducted with 26 policymakers and key stakeholders in two communities about climate adaptation, hunting and fishing, economic development, and fertility and reproductive health. Participants link fertility outcomes to disparate community socioeconomic circumstances that affect individual access to education and financial mobility. Workforce and education challenges in Greenland limit ability to expand culturally grounded reproductive healthcare. Coordinating healthcare, education, and housing policy may improve material resources to support fertility decisions in Greenland. We contextualize drivers of fertility decisions within Greenland's climate adaptation policy options.Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.
Soluble immune checkpoints are dysregulated in patients with sickle cell disease and correlate with inflammatory mediators, autoantibodies, immune cell profiles, and clinical outcomes
Li, Pucka, Houran et al
medRxiv (2025)
Abstract: Sickle cell disease (SCD) is a chronic condition characterized by inflammation, immune dysregulation, and debilitating pain.This study investigates soluble immune checkpoints (sICPs) and their associations with inflammatory mediators, immune cell profiles, autoantibodies, and clinical outcomes in SCD.Peripheral blood samples from 50 SCD patients and 40 demographic-matched healthy controls (HCs) were analyzed for 37 sICPs, 80 inflammatory mediators, and 18 autoantibodies using multiplex assays, alongside immune cell profiles via flow cytometry. Pain and quality of life (QoL) were assessed through patient-reported outcome measures (PROMs).Twenty-three sICPs, including arginase-1, BTLA, CD27, CD28, CD47, CD80, CD96, CD134, CD137, CD152, GITR, HVEM, IDO, LAG-3, MICA, MICB, Nectin-2, PD-1, Siglec-7, Siglec-9, TIM-3, TIMD-4, and VISTA, were significantly elevated in SCD patients compared to HCs. These sICPs correlated with multiple proinflammatory mediators (e.g., IL-18), autoantibodies (e.g., MPO), and immune cell activation markers (e.g., CD38/HLA-DR on CD8 T cells). Notably, CD28, CD152, HVEM, and VISTA were strongly associated with systemic inflammation and immune cell activation, while BTLA, LAG-3, PD-1, and CD80 correlated with pain and anxiety scores and QoL.This study highlights complex interactions between sICPs, immune activation, inflammation, and clinical outcomes in SCD, underscoring their potential as biomarkers or therapeutic targets to alleviate inflammation and improve QoL in this challenging clinical population.
RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer
Sethna, Guasp, Reiche et al
Nature (2025)
Abstract: A fundamental challenge for cancer vaccines is to generate long-lived functional T cells that are specific for tumour antigens. Here we find that mRNA-lipoplex vaccines against somatic mutation-derived neoantigens may solve this challenge in pancreatic ductal adenocarcinoma (PDAC), a lethal cancer with few mutations. At an extended 3.2-year median follow-up from a phase 1 trial of surgery, atezolizumab (PD-L1 inhibitory antibody), autogene cevumeran1 (individualized neoantigen vaccine with backbone-optimized uridine mRNA-lipoplex nanoparticles) and modified (m) FOLFIRINOX (chemotherapy) in patients with PDAC, we find that responders with vaccine-induced T cells (n = 8) have prolonged recurrence-free survival (RFS; median not reached) compared with non-responders without vaccine-induced T cells (n = 8; median RFS 13.4 months; P  =  0.007). In responders, autogene cevumeran induces CD8+ T cell clones with an average estimated lifespan of 7.7 years (range 1.5 to roughly 100 years), with approximately 20% of clones having latent multi-decade lifespans that may outlive hosts. Eighty-six percent of clones per patient persist at substantial frequencies approximately 3 years post-vaccination, including clones with high avidity to PDAC neoepitopes. Using PhenoTrack, a novel computational strategy to trace single T cell phenotypes, we uncover that vaccine-induced clones are undetectable in pre-vaccination tissues, and assume a cytotoxic, tissue-resident memory-like T cell state up to three years post-vaccination with preserved neoantigen-specific effector function. Two responders recurred and evidenced fewer vaccine-induced T cells. Furthermore, recurrent PDACs were pruned of vaccine-targeted cancer clones. Thus, in PDAC, autogene cevumeran induces de novo CD8+ T cells with multiyear longevity, substantial magnitude and durable effector functions that may delay PDAC recurrence. Adjuvant mRNA-lipoplex neoantigen vaccines may thus solve a pivotal obstacle for cancer vaccination.© 2025. The Author(s).
Showing 1-4 of 1125 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Activin A靶点信息
英文全称:Activin receptor type-1
中文全称:激活素受体-1
种类:Homo sapiens
上市药物数量:1详情
临床药物数量:5详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定